IBRX ImmunityBio, Inc.

ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc.

$5.17  +0.20 (4.02%)
As of 10/03/2022 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/10/2021
Outstanding shares:  400,304,106
Average volume:  3,060,055
Market cap:   $1,977,502,284
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNSP0B8
Valuation   (See tab for details)
PE ratio:   -5.38
PB ratio:   -5.93
PS ratio:   0.00
Return on equity:   111.15%
Net income %:   -46,113.72%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy